Raw Materials & Excipients Management – Page 23

Supplier change not evaluated during routine operations – risk-based change impact assessment

How to Address Supplier Change Evaluation Gaps in Routine Operations In the fast-paced world of pharmaceutical manufacturing, unforeseen supplier changes can lead to significant compliance and quality issues. Failing to…

Inadequate vendor qualification during supply disruption – how to prevent repeat supplier failures

Addressing Insufficient Vendor Qualification During Supply Chain Disruptions Pharmaceutical manufacturers face numerous challenges when supply disruptions occur, particularly regarding the qualification of vendors supplying critical materials. Inadequate vendor qualification during…

Raw material change implemented without assessment during post-approval change review – CAPA to prevent repeat failures

Recognizing the early signs of a raw material change that has not been adequately assessed is crucial. Symptoms may include:Click to read the full article.

Supplier audit findings escalated during supplier onboarding – audit CAPA remediation framework

Typically, symptoms of supplier audit findings may present themselves as discrepancies during raw material testing, deviations from specifications, or non-compliance with documented procedures. Symptoms can vary widely based on the…

Unapproved material substitution during post-approval change review – CAPA to prevent repeat failures

Managing Unapproved Material Substitution in Post-Approval Change Reviews Unapproved material substitutions during post-approval changes pose significant risks to product quality and compliance. This situation often arises in the lifecycle of…

Supplier audit findings escalated during supply disruption – audit CAPA remediation framework

The initial signals indicating that supplier audit findings have escalated during a supply disruption can manifest in multiple ways. Typically, they may include:Click to read the full article.

Unapproved material substitution during routine operations – CAPA to prevent repeat failures

Identifying material substitution issues early can save time and resources. The following symptoms should trigger immediate investigation:Click to read the full article.

Vendor change implemented without approval during supplier onboarding – inspection questions regulators ask

Investigating Unapproved Vendor Changes During Supplier Onboarding In the pharmaceutical industry, the integrity of raw materials is critical to the safety, efficacy, and quality of products. An investigation into the…

Change impact underestimated during supplier change – regulatory expectations for material changes

Recognizing early warning signs is crucial for mitigating risks associated with raw material changes. Some typical symptoms and signals include:Click to read the full article.

Critical supplier risk not assessed during supplier onboarding – supplier risk classification strategy

Identifying symptoms of critical supplier risks not assessed during onboarding can prevent larger issues downstream. Common signals that may indicate unassessed supplier risks include:Click to read the full article.

Supplier change not evaluated during post-approval change review – CAPA to prevent repeat failures

Identifying issues arising from unassessed supplier changes often starts on the manufacturing floor or within laboratory settings. Symptoms may manifest as:Click to read the full article.

Supplier audit findings escalated during routine supplier audit – how to prevent repeat supplier failures

Recognizing early indicators of supplier-related issues is crucial for maintaining operational continuity. Symptoms may manifest as discrepancies in raw material quality, deviations from established specifications, or increased complaints during production.…